Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Supplements not significantly associated with a statistically significant difference in outcomes included: alpha-lipoic acid (β = −106, CI95%: −240 to 28.5; p = 0.1), vitamin B12 (β = −56.5, CI95%: −119 to 6.02; p = 0.08), calcium (β = 18.13, CI95%: −56.2 to 92.5; p = 0.6), vitamin D (β = −26.5, CI95%: −96.4 to 43.3; p = 0.5), estrogen (β = −51.0, CI95%: −185 to 82.9; p = 0.5), NADH (β = 53.5, CI95%: −235 to 342; p = 0.7), intranasal glutathione (β = −168, CI95%: −456 to 121; p = 0.3), inosine (β = 82.8, CI95%: −442 to 607; p = 0.8), iron (β = 17.1, CI95%: −122 to 156; p = 0.8), edible marijuana (β = 64.0, CI95%: −43.7 to 172; p = 0.2), inhaled marijuana (β = 45.0, CI95%: −98.0 to 188; p = 0.5), melatonin (β = 53.7, CI95%: −16.2 to 123; p = 0.1), probiotics (β = 17.7, CI95%: −56.6- 92.0; p = 0.6), quercetin (β = −134, CI95%: −362 to 94.6; p = 0.3), resveratrol (β = −163, CI95%: −334 to 8.52; p = 0.06), multivitamin/multimineral supplement (β = −21.8, CI95%: −94.2- 50.6; p = 0.6), N-acetyl cysteine (β = −46.7, CI95%: −168 to 74.8; p = 0.5), low-dose naltrexone (β = −53.5, CI95%: −460 to 353; p = 0.8), fava bean (β = −154, CI95%: −476 to 168; p = 0.3), high dose thiamine (oral) (β = −136, CI95%: −273 to 1.20; p = 0.052), lion’s mane mushroom (β = −70.5, CI95%: −232 to 91.0; p = 0.4), other medicinal mushrooms (β = −61.8, CI95%: −168 to 292; p = 0.6), testosterone (intramuscular, β = 101, CI95%: −308 to 509; p = 0.6; and topical, β = −6.53, CI95%: −247- 260; p = 0.9), mannitol (β = −97.3, CI95%: −285- 90.8; p = 0.3), IV micronutrient therapy (β = −419, CI95%: −1330 to 487; p = 0.4), IM micronutrient therapy (β = −57.6, CI95%: −75.2 to 40.0; p = 0.9), red light therapy (β = 6.03, CI95%: −158 to 170; p = 0.9), and farnesol (β = −235, CI95%: −207 to 754; p = 0.6).
Source: 3. Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
To measure supplement use, participants were given a list of commonly used supplements among people with PD, as determined by a literature review, clinical experience, patient feedback, and academic expertise in nutrition and neurological health among the study team.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Parkinson Symptom Severity and Use of Nutraceuticals
Study design awaiting verification · Nutrients · 2023
Original publication title
Parkinson Symptom Severity and Use of Nutraceuticals
© 2023 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Background: It is estimated that half of the individuals with Parkinson’s disease (PD) use some form of over-the-counter vitamin, herbal supplement or nutraceutical. The goal of this study was to survey individuals with PD about their use of the nutraceuticals and evaluate the association of the nutraceutical with the severity of symptoms. Methods: Participants with self-reported idiopathic PD within the 2021 cohort (n = 1084) were included in a cross-sectional study to assess association of nutraceuticals with symptom severity via linear regression analysis.
PD severity was measured using the patient-reported outcomes in PD, and supplement use reflected self-reported consistent use over the previous six months. All regression analyses adjusted for age, gender, income and years since diagnosis. The use of the term progression refers to PRO-PD scores adjusted for years since diagnosis. Results: The most frequently used supplements were vitamin D (71%), B12 (44%), vitamin C (38%) and fish oil (38%). None of the supplements being used were associated with statistically significant worse outcomes.
Nutraceuticals associated with improved outcomes were Ginkgo biloba (GB), NAD+ or its precursors, 5-methyltetrahydrofolate, glutathione, mucuna, CoQ10, low dose lithium, curcumin, homocysteine factors, DHEA, coconut oil, vitamin C, and omega-3 fatty acids (fish oil). Conclusions: These data suggest that in a real-world setting, some over-the-counter supplements are associated with fewer patient-reported symptoms. Supplements with significant associations with fewer symptoms have biological plausibility and future clinical trials should be explored.
Authors’ abstract
Background: It is estimated that half of the individuals with Parkinson’s disease (PD) use some form of over-the-counter vitamin, herbal supplement or nutraceutical. The goal of this study was to survey individuals with PD about their use of the nutraceuticals and evaluate the association of the nutraceutical with the severity of symptoms. Methods: Participants with self-reported idiopathic PD within the 2021 cohort (n = 1084) were included in a cross-sectional study to assess association of nutraceuticals with symptom severity via linear regression analysis.
PD severity was measured using the patient-reported outcomes in PD, and supplement use reflected self-reported consistent use over the previous six months. All regression analyses adjusted for age, gender, income and years since diagnosis. The use of the term progression refers to PRO-PD scores adjusted for years since diagnosis. Results: The most frequently used supplements were vitamin D (71%), B12 (44%), vitamin C (38%) and fish oil (38%). None of the supplements being used were associated with statistically significant worse outcomes.
Nutraceuticals associated with improved outcomes were Ginkgo biloba (GB), NAD+ or its precursors, 5-methyltetrahydrofolate, glutathione, mucuna, CoQ10, low dose lithium, curcumin, homocysteine factors, DHEA, coconut oil, vitamin C, and omega-3 fatty acids (fish oil). Conclusions: These data suggest that in a real-world setting, some over-the-counter supplements are associated with fewer patient-reported symptoms. Supplements with significant associations with fewer symptoms have biological plausibility and future clinical trials should be explored.
Publication and source details
Original title: Parkinson Symptom Severity and Use of Nutraceuticals
Laurie K. Mischley; Joshua Farahnik; Ludwig Mantay; Jamie Punzi; Kayla Szampruch; Tyrice Ferguson; Devon J. Fox
Nutrients · 2023
* Correspondence: lmischley@bastyr.edu© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).community donations made by Bill and Sondra Fondren and Mark Claude, Sondra Wolfe Elias, Debbie Krasnow, and other anonymous donorsThis research was funded by community donations made by Bill and Sondra Fondren and Mark Claude, Sondra Wolfe Elias, Debbie Krasnow, and other anonymous donors.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T07:54:06.458816+00:00
DOI: 10.3390/nu15040802 · PMC9966010